Table 3.

Primary adverse outcomes during the follow-up period.

ADVERSE OUTCOMES	TOTAL, n (%)
30-day MACCE – n (%)	9 (1.5%)
Cardiac death	6 (1.0%)
Ischemic stroke	0 (0.0%)
Definite stent thrombosis	(0.5%)
TLR	2 (0.3%)
TVR	3 (0.5%)
1-year MACCE – n (%)	39 (6.3%)
Cardiac death	10 (1.6%)
Ischemic stroke	0 (0.0%)
Definite stent thrombosis	17 (2.8%)
TLR	22 (3.6%)
TVR	29 (4.7%)

MACCE – major adverse cardiovascular and cerebrovascular events; TLR – target lesion revascularization; TVR – target vessel revascularization.